#ASCO14 - Poster: Final analysis of a large, open-label global early access protocol with abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

CHICAGO, IL USA (UroToday.com) - Presented by Cora N. Sternberg,1 Gedske Daugaard,2 Lajos Géczi,3 Sebastien J. Hotte,4 Paul N. Mainwaring,5 Fred Saad,6 Ciro Souza,7 Miah H. Tay,8 José M. Tello Garrido,9 Luca Galli,10 Anil Londhe,11 Peter De Porre,12 Dan Atlan,13 Betty Goon,11 Emma Lee,12 Tracy McGowan,11 Vahid Naini,14 Mary B. Todd,15 Arturo Molina,16 and Daniel J. George17 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 sternberg poster thumb

Click HERE to listen to an exclusive interview with Cora N. Sternberg, MD, one of the authors of the study

1San Camillo and Forlanini Hospitals, Rome, Italy
2Rigshospitalet, Copenhagen, Denmark
3National Institute of Oncology, Budapest, Hungary
4McMaster University, Hamilton, ON, Canada
5ICON Cancer Care, Brisbane, Australia
6University of Montréal, Montréal, QC, Canada
7Center for Oncology, Hospital Sírio-Libanês, São Paulo, Brazil
8OncoCare Cancer Centre, Singapore
9Centro Oncologico Belenus, Cuernavaca, Mexico
10University of Pisa, Pisa, Italy
11Janssen Research & Development, Horsham, PA USA
12Janssen Research & Development, Beerse, Belgium
13Janssen Europe, Paris, France
14Janssen Research & Development, Los Angeles, CA USA
15Janssen Global Services, Raritan, NJ USA
16Janssen Research & Development, Menlo Park, CA USA
17Duke Cancer Institute, Durham, NC USA